Skip to main content

Advertisement

Log in

A case series of patients treated with inotuzumab ozogamicin for acute lymphoblastic leukemia relapsed after allogeneic hematopoietic cell transplantation

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

This single-center retrospective study was performed in consecutive patients with acute lymphoblastic leukemia who relapsed after allogeneic hematopoietic cell transplantation (HCT) and received salvage therapy using inotuzumab ozogamicin (InO). Ten patients (median age: 27 years) treated between June 2018 and July 2020 who met the eligibility criteria were included in this study. Nine patients received InO in one cycle and seven of these patients achieved complete hematological remission after salvage chemotherapy including InO. Negative minimal residual disease was confirmed in all four evaluable patients. Eight patients were successfully bridged to the subsequent HCT. After HCT, veno-occlusive disease (VOD) developed in three patients, and caused the death of one. No patient received maintenance therapy. At present, five patients are disease-free and alive, and the overall and progression-free survival rates at 1 year were 60% and 40%, respectively. High rates of disease remission and bridging to HCT with comprehensive treatments including InO may have contributed to favorable outcomes. However, further investigation is needed to reduce post-HCT complications including VOD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Spyridonidis A, Labopin M, Schmid C, Volin L, Yakoub-Agha I, Stadler M, et al. Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT. Leukemia. 2012;26(6):1211–7.

    Article  CAS  Google Scholar 

  2. Gökbuget N, Stanze D, Beck J, Diedrich H, Horst HA, Hüttmann A, et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood. 2012;120(10):2032–41.

    Article  Google Scholar 

  3. Kako S, Kanamori H, Kobayashi N, Shigematsu A, Nannya Y, Nakamae M, et al. Outcome after first relapse in adult patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia. Br J Haematol. 2013;161(1):95–103.

    Article  Google Scholar 

  4. Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375(8):740–53.

    Article  CAS  Google Scholar 

  5. Kantarjian HM, DeAngelo DJ, Stelljes M, Liedtke M, Stock W, Gökbuget N, et al. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer. 2019;125(14):2474–87.

    Article  CAS  Google Scholar 

  6. Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera JM, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836–47.

    Article  CAS  Google Scholar 

  7. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507–17.

    Article  Google Scholar 

  8. Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, et al. Phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369(19):1783–96.

    Article  CAS  Google Scholar 

  9. Kantarjian HM, DeAngelo DJ, Advani AS, Stelljes M, Kebriaei P, Cassaday RD, et al. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. Lancet Haematol. 2017;4(8):e387–98.

    Article  Google Scholar 

  10. Fujishima N, Uchida T, Onishi Y, Jung CW, Goh YT, Ando K, et al. Inotuzumab ozogamicin versus standard of care in Asian patients with relapsed/refractory acute lymphoblastic leukemia. Int J Hematol. 2019;110(6):709–22.

    Article  CAS  Google Scholar 

  11. Okura M, Ida N, Yamauchi T. Clinical significance of inotuzumab ozogamicin in non-transplant patients with relapsed acute lymphoblastic leukemia: a report of four cases. Intern Med. 2020;59(16):2047–51.

    Article  Google Scholar 

  12. Fan H, Robetorye RS. Real-time quantitative reverse transcriptase polymerase chain reaction. Methods Mol Biol. 2010;630:199–213.

    Article  CAS  Google Scholar 

  13. van der Velden VH, Hochhaus A, Cazzaniga G, Szczepanski T, Gabert J, van Dongen JJ. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia. 2003;17(6):1013–34.

    Article  Google Scholar 

  14. Ray A, Cowan-Jacob SW, Manley PW, Mestan J, Griffin JD. Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study. Blood. 2007;109(11):5011–5.

    Article  CAS  Google Scholar 

  15. Mohty M, Malard F, Abecassis M, Aerts E, Alaskar AS, Aljurf M, et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2016;51(7):906–12.

    Article  CAS  Google Scholar 

  16. Jabbour E, Ravandi F, Kebriaei P, Huang X, Short NJ, Thomas D, et al. Salvage chemoimmunotherapy with inotuzumab ozogamicin combined with mini–hyper-CVD for patients with relapsed or refractory philadelphia chromosome-negative acute lymphoblastic leukemia: a phase 2 clinical trial. JAMA Oncol. 2018;4(2):230–4.

    Article  Google Scholar 

  17. Jabbour E, Sasaki K, Ravandi F, Huang X, Short NJ, Khouri M, et al. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. Cancer. 2018;124(20):4044–55.

    Article  CAS  Google Scholar 

  18. Jabbour E, O’Brien S, Huang X, Thomas D, Rytting M, Sasaki K, et al. Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody. Am J Hematol. 2015;90(3):193–6.

    Article  CAS  Google Scholar 

  19. Kantarjian HM, Stock W, Cassaday RD, DeAngelo DJ, Jabbour E, O’Brien SM, et al. Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia in the INO-VATE trial: CD22 pharmacodynamics, efficacy, and safety by baseline CD22. Clin Cancer Res. 2021;27(10):2742–54.

    Article  CAS  Google Scholar 

  20. Fingrut W, Davis W, McGinnis E, Dallas K, Ramadan K, Merkeley H, et al. Reevaluating patient eligibility for inotuzumab ozogamicin based on CD22 expression: is dim expression sufficient? Curr Oncol. 2020;28(1):252–9.

    Article  Google Scholar 

  21. Kantarjian HM, Su Y, Jabbour EJ, Bhattacharyya H, Yan E, Cappelleri JC, et al. Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia. Cancer. 2018;124(10):2151–60.

    Article  CAS  Google Scholar 

  22. Tachibana T, Matsumoto K, Tanaka M, Hagihara M, Motohashi K, Yamamoto W, et al. Outcome and prognostic factors among patients who underwent a second transplantation for disease relapse post the first allogeneic cell transplantation. Leuk Lymphoma. 2017;58(6):1403–11.

    Article  Google Scholar 

  23. Mohty M, Malard F, Abecassis M, Aerts E, Alaskar AS, Aljurf M, et al. Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2015;50(6):781–9.

    Article  CAS  Google Scholar 

  24. Corbacioglu S, Jabbour EJ, Mohty M. Risk factors for development of and progression of hepatic veno-occlusive disease/sinusoidal obstruction syndrome. Biol Blood Marrow Transplant. 2019;25(7):1271–80.

    Article  Google Scholar 

  25. Richardson PG, Riches ML, Kernan NA, Brochstein JA, Mineishi S, Termuhlen AM, et al. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood. 2016;127(13):1656–65.

    Article  CAS  Google Scholar 

  26. Wadleigh M, Richardson PG, Zahrieh D, Lee SJ, Cutler C, Ho V, et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood. 2003;102(5):1578–82.

    Article  CAS  Google Scholar 

  27. Ho VT, Martin AS, Pérez WS, Steinert P, Zhang MJ, Chirnomas D, et al. Prior Gemtuzumab ozogamicin exposure in adults with acute myeloid leukemia does not increase hepatic veno-occlusive disease risk after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research analysis. Biol Blood Marrow Transplant. 2020;26(5):884–92.

    Article  CAS  Google Scholar 

  28. Giebel S, Czyz A, Ottmann O, Baron F, Brissot E, Ciceri F, et al. Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer. 2016;122(19):2941–51.

    Article  CAS  Google Scholar 

  29. Akahoshi Y, Nishiwaki S, Mizuta S, Ohashi K, Uchida N, Tanaka M, et al. Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer Sci. 2019;110(10):3255–6.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Appreciate all physician of the institutions who treated, consulted, and retreated before and after treating at Kanagawa Cancer Center: Shonan Kamakura General Hospital, Kitasato University School of Medicine, Yokohama Tsurugamine Hospital, Fujisawa City Hospital, Yokohama Rosai Hospital, Sagamino Hospital, Toranomon Hospital, and Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital.

Funding

This study has no funding support.

Author information

Authors and Affiliations

Authors

Contributions

AH collected data and wrote the manuscript. TT designed the research and wrote the manuscript. TA and MT were the physician of the enrolled patients. MT and HK were the directors of department. HN supervised the study.

Corresponding author

Correspondence to Takayoshi Tachibana.

Ethics declarations

Conflict of interest

All authors except the following have no conflict of interest to declare. TT reports personal fees from Otsuka, personal fees from Novartis, personal fees from Pfizer, personal fees from BMS, personal fees from Daiichi Sankyo, personal fees from Astellas, outside the submitted work.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Izumi, A., Tachibana, T., Ando, T. et al. A case series of patients treated with inotuzumab ozogamicin for acute lymphoblastic leukemia relapsed after allogeneic hematopoietic cell transplantation. Int J Hematol 115, 69–76 (2022). https://doi.org/10.1007/s12185-021-03217-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-021-03217-4

Keywords

Navigation